Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirna collaborator announces Huntington’s breakthrough
The results were published by Dr Beverly Davidson of the University of Iowa, an academic collaborator of Sirna, Targeted Genetics’ partner for the development of novel therapies for
The results were published by Dr Beverly Davidson of the University of Iowa, an academic collaborator of Sirna, Targeted Genetics’ partner for the development of novel therapies for
GTI-2040 is a highly specific inhibitor of R2, a component of ribonucleotide reductase, which can behave as a malignant determinant for cancer growth and metastasis, and is abnormally
The effects were found to be significantly better than placebo and comparable to that of an approved atypical antipsychotic agent. No serious adverse events attributable to ocaperidone were
Rotateq is Merck’s investigational vaccine to protect against rotavirus gastroenteritis. It is an oral, liquid vaccine that contains five human serotypes – G1, G2, G3, G4 and P1.
The phase II trial will further assess the ability of D-63153, a fourth generation LHRH (luteinizing hormone releasing hormone) antagonist, to suppress testosterone levels in a dose-dependent manner
The company’s efforts will focus on the recent FDA-approved label change, based on a landmark four-year study, indicating that weight loss with Xenical (orlistat) reduces the risk of
The license covers patents, patent applications, intellectual property, data and certain other assets relating to novel inhibitors of cortisol synthesis. Included within the licensed assets is an issued
Reliant began promoting Lescol (fluvastatin sodium) and Lescol XL (fluvastatin sodium extended-release tablets) in January 2001 under a five-year agreement. Under the terms of the extended agreement, Reliant
The UCLA and Veterans Affairs Greater Los Angeles Healthcare System study demonstrated that for arthritis sufferers at high risk for gastrointestinal problems who traditionally may have used a
The study, which included 828 patients with chronic insomnia, augments the findings in Sepracor’s first landmark, six-month study of Lunesta (eszopiclone). This long-term study included a two-week discontinuation